A Belgian cellular therapy company has announced data from a phase 2a clinical trial of a therapy for an incurable liver condition.
Promethera Biosciences SA is working on a product called HepaStem that takes liver stem cells, expands them in the laboratory and gives them via IV to patients with a liver condition known as acute-on-chronic liver failure (ACLF). The stem cells migrate through the blood and settle in the liver, supporting regeneration.
Today, the only treatment for ACLF is a liver transplant. “Looks like the data is good and showing that the dosing protocol is safe,” said Scott Jones, Vice President, Scientific Affairs, at BioBridge Global.
“Preliminarily, the data is showing liver function improvement. Still early to say what the true effect is, but it looks very promising.”